Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Authors: Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, et al.
Journal
JAMA
Year
2022
Citations
600
Type
Clinical Trial
Subject
Human
Condition
Obesity / Weight Management
TL;DR
STEP 8 trial: once-weekly semaglutide 2.4mg produced greater weight loss than daily liraglutide 3.0mg over 68 weeks in adults with overweight or obesity.
View Paper
DOI: 10.1001/jama.2021.23619
Abstract
Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.. To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity.. Randomized, open-label, 68-week, phase 3b.